Dr. Emilie Schindler joined Certara as Associate Director, Integrated Drug Development, in June 2018. She is currently a consultant working on PK and PK/PD modeling projects in various therapeutic areas.
Emilie received her PharmD in 2011 from Strasbourg University, France. During her studies, she was involved in PBPK modeling projects as part of her internships at Hoffmann-La Roche, Switzerland, and AstraZeneca, Sweden. In 2018, she obtained her PhD in Pharmaceutical Biosciences from Uppsala University, Sweden. Her research focused on pharmacometrics to improve clinical benefit assessment in oncology, integrating pharmacokinetics, biomarkers, tumor response, and clinical outcome data. During her PhD, she spent three months as an intern at Genentech, CA, USA, developing a pharmacometric approach to analyze patient-reported outcome data in oncology.
Before joining Certara, Emilie worked as a consultant in pharmacometrics at Uppsala University and at Pharmetheus, Sweden, where she performed PK/PD modeling analyses in various disease areas, including multiple sclerosis and cardiovascular diseases.